Research of the Antiepyleptic Activity of the New Amydic Derivative Valproic Acid and 1,3,4-Thiadiazole

Malygin A. S.
Resident Physician, Chair for Pharmacology and Clinical Pharmacology¹

1 - Tver State Medical University, Tver, Russia

Malygin A.S.; E-mail: dr.a.s.m@yandex.ru

None declared.

The study had no sponsorship.

Aim: Experimental evaluation of the acute toxicity and neurotoxicity of a new amide derivative of valproic acid and 1,3,4-thiadiazole. Materials and Methods: The acute toxicity of N-(5-ethyl-1,3,4-thiadiazol-2-yl)-2-propylpentanamide (valprazolamide) was evaluated by probit analysis in experiments in mice. Neurotoxicity was determined in a rotating rod test and pull-up bar test in mice. The effect of valprazolamide on the exploratory behavior of mice in «open field» test and in a «dark/light transition» test was evaluated. Results: The DL ₅₀ and TD₅₀ values of valprazolamide (intraperitoneally) for mice were 924.8 (756.9-1063.7) mg/kg and 456.7 (325.4–603.6) mg/kg, respectively. Conclusion: A new amide derivative of valproic acid and 1,3,4-thiadiazole (valprazolamide) belongs to the group of low-toxic substances.

antiepileptic drugs, valproic acid, 1,3,4-thiadiazole, acute toxicity, neurotoxicity

10.29234/2308-9113-2019-7-3-37-46

1. Freydkova N.V., Pylayeva O.V., Mukhin K.Yu. Val'parin KHR v epilepsii (obzor literatury i opisaniye klinicheskikh sluchayev) [Valparin XP in the treatment of epilepsy (review of the literature and the description of clinical cases)]. Russkiy zhurnal detskoy nevrologii [Russian Journal of Pediatric Neurology] 2015; 10 (3): 37-42. (In Russ.)

2. Perucca E. Pharmacological and therapeutic properties of valproate: a summary after 35 years of clinical experience. CNS Drugs. 2012;16(10): 695-714.

3. Pilyugina M.S. Khronicheskaya intoksikatsiya preparatov val'proyevoy kisloty: diagnostika i metody korrektsii [Chronic intoxication with valproic acid preparations: diagnosis and methods of correction]. Vestnik Klinicheskoy bol'nitsy №51 [Bulletin of the Clinical Hospital №51] 2011; 2-3: 75-80. (In Russ.)

4. Shnayder N.A., Dmitrenko D.V. Khronicheskaya intoksikatsiya val'proyevoy kislotoy v epileptologii: diagnostika i lecheniye [Chronic intoxication with valproic acid in epileptology: diagnosis and treatment]. Nevrologiya, neyropsikhiatriya, psikhosomatika [Neurology, neuropsychiatry, psychosomatics] 2016; 8 (2): 94-99. (In Russ.)

5. Sztajnkrycer M.D. Valproic acid toxicity: overview and management. J Toxicol Clin Toxicol. 2002; 40(6):789-801.

6. Collins-Yoder A., Lowell J. Valproic acid: special considerations and targeted monitoring. J. Neurosci Nurs. 2017; 49 (1): 56-61.

7. Leonova M.V., Ivzhits M.A., Tishchenkova I.F. et al. Terapevticheskiy lekarstvennyy monitoring antikonvul'santov u detey v real'noy praktike [Therapeutic drug monitoring of anticonvulsants in children in actual practice]. Epilepsiya i paroksizmal'nyye sostoyaniya [Epilepsy and paroxysmal states] 2017; 9 (1): 26-34. (In Russ.)

8. Malygin A.S., Popov N.S., Demidova M.A., Kudryashova M.N., Gorshkova M.A. Ispol'zovaniye VEZHKH-mass-spektrometrii dlya terapevticheskogo lekarstvennogo monitoringa val'proatov [Use of HPLC-mass spectrometry for therapeutic drug monitoring of valproates]. Verkhnevolzhskiy meditsinskiy zhurnal [Upper Volga Medical Journal] 2018; 17 (2): 27-33. (In Russ.)

9. Yakunina A.V., Poverennova I.Ye. Rol' terapevticheskogo lekarstvennogo monitoringa pri ispol'zovanii protivoepilepticheskikh preparatov [The role of therapeutic drug monitoring when using antiepileptic drugs]. Epilepsiya i paroksizmal'nyye sostoyaniya [Epilepsy and paroxysmal states] 2016; 8 (3): 66-73. (In Russ.)

10. Jorge Diaz R.A., Enrique Cami Gerardo. Salts of 5-amino-2-sulfonamide-1,3,4-thiadiazole, a structural and analog of acetazolamide, show interesting carbonic anhydrase inhibitory properties, diuretic, and anticonvulsant action. Journal of Enzyme Inhibition and Medicinal Chemistry 2016; 12(6): 1102-1111.

11. Trojnar M.K., Wierzchowska-Cioch E., Krzyzanowski M., Jargiełło M., Czuczwar S.J. New generation of valproic acid. Pol J Pharmacol. 2004; 56 (3): 283-8.

12. Zheltukhin N.K., Demidova M.A., Korotkonozhkin A.V., Popov N.S., Skachilova S.Ya., Sadchikova N.P., Malygin A.S. N- (5-Etil-1,3,4-tiadiazol-2-il) -2-propilpentanamid, obladayushchiy protivoepilepticheskoy i obezbolivayushchey aktivnostyami [N- (5-Ethyl-1,3,4-thiadiazol-2-yl) -2-propylpentanamide, which has antiepileptic and analgesic activities]. Russian Federation Patent 267288 filed by OAO VNTS BAV 13.03.2018 and issued 20.11.2018. (In Russ.)

13. Prikaz MZ RF ot 01.04.2016 № 199n «Pravila nadlezhashchey laboratornoy praktiki» [Order of the Ministry of Health of the Russian Federation of 01.04.2016 No. 199n «Rules of good laboratory practice»]. (In Russ.)

14. Mironov A.N. Rukovodstvo po provedeniyu doklinicheskikh issledovaniy lekarstvennykh sredstv [Manual for preclinical studies of drugs]. Moscow: Grif i K., 2012. (In Russ.)

15. Berezovskaya I.V. Prognoz bezopasnosti lekarstvennykh sredstv v doklinicheskikh toksikologicheskikh issledovaniyakh [Forecast of drug safety in preclinical toxicological studies]. Toksikologicheskiy vestnik [Toxicological Bulletin] 2010; (5): 17-22. (In Russ.)

16. Voronina T.A., Garibova T.L, Krayneva V.A Povedencheskiye eksperimental'nyye modeli depressii [Behavioral experimental models of depression]. Farmakokinetika i farmakodinamika [Pharmacokinetics and pharmacodynamics] 2017; 3: 14-19. (In Russ.)

17. Malygin A.S., Lomonosova I.A. Bogomolova O.A., Demidova M.A. Vliyaniye val'prazolamida na oriyentirovochno-issledovatel'skoye povedeniye myshey [Impact of Valprazolamide on the Exploratory Behavior in Mice]. Meditsina [Medicine] 2018; 4: 109-119. (In Russ.)

18. Dogan H., Duran A., Rollas S. et al. Synthesis of new 2,5-Disubstituted-1,3,4-thiadiazoles and preliminary evaluation of anticonvulsant and antimicrobial activities. Bioorg. Med. Chem. 2002; 10: 2893-2898.

19. Matysiak J. Biological and pharmacological activities of 1,3,4-thiadiazole based compounds. Mini-Reviews in Medicinal Chemistry 2015; 15(9):762-775.